Literature DB >> 11519638

Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder.

E D Levin1, C K Conners, D Silva, W Canu, J March.   

Abstract

Acute nicotine treatment has been found to reduce symptoms of attention deficit/hyperactivity disorder in adults (E. D. Levin, C. K. Conners, et al., 1996). In this study, chronic nicotine effects were compared with placebo and methylphenidate. Acute and chronic nicotine treatment significantly attenuated the rise in hit reaction time standard error over session blocks on the Conners Continuous Performance Test (C. K. Conners et al., 1996). Acute nicotine significantly reduced severity of clinical symptoms on the Clinical Global Impressions scale (National Institute of Mental Health, 1985). Nicotine caused a significant decrease in self-report of depressive mood as measured by the Profile of Mood States test (D. M. McNair, M. Lorr, & L. F. Droppleman, 1981). This small study (40 participants) provided evidence that nicotine treatment can reduce severity of attentional deficit symptoms and produce improvement on an objective computerized attention task.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11519638     DOI: 10.1037/1064-1297.9.1.83

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  61 in total

1.  Response requirement and increases in accuracy produced by stimulant drugs in a 5-choice serial reaction-time task in rats.

Authors:  Mikhail N Koffarnus; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

2.  Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.

Authors:  Paula L Vieira-Brock; Eleanor I Miller; Shannon M Nielsen; Annette E Fleckenstein; Diana G Wilkins
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-09-18       Impact factor: 3.205

3.  A practical approach to objective attention deficit/hyperactivity disorder diagnosis and management.

Authors:  C Thomas Gualtieri
Journal:  Psychiatry (Edgmont)       Date:  2005-07

4.  Substance use through adolescence into early adulthood after childhood-diagnosed ADHD: findings from the MTA longitudinal study.

Authors:  Brooke S G Molina; Andrea L Howard; James M Swanson; Annamarie Stehli; John T Mitchell; Traci M Kennedy; Jeffery N Epstein; L Eugene Arnold; Lily Hechtman; Benedetto Vitiello; Betsy Hoza
Journal:  J Child Psychol Psychiatry       Date:  2018-01-08       Impact factor: 8.982

5.  Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial.

Authors:  F Joseph McClernon; F Berry Hiott; Eric C Westman; Jed E Rose; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2006-09-15       Impact factor: 4.530

Review 6.  Constitutional mechanisms of vulnerability and resilience to nicotine dependence.

Authors:  N Hiroi; D Scott
Journal:  Mol Psychiatry       Date:  2009-02-24       Impact factor: 15.992

7.  Stimulant treatment of ADHD and cigarette smoking: a meta-analysis.

Authors:  Erin N Schoenfelder; Stephen V Faraone; Scott H Kollins
Journal:  Pediatrics       Date:  2014-05-12       Impact factor: 7.124

8.  Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder.

Authors:  Alexandra S Potter; Paul A Newhouse
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

9.  Methylphenidate does not influence smoking-reinforced responding or attentional performance in adult smokers with and without attention deficit hyperactivity disorder (ADHD).

Authors:  Scott H Kollins; Erin Schoenfelder; Joseph S English; F Joseph McClernon; Rachel E Dew; Scott D Lane
Journal:  Exp Clin Psychopharmacol       Date:  2013-10       Impact factor: 3.157

Review 10.  ADHD and smoking: from genes to brain to behavior.

Authors:  Francis Joseph McClernon; Scott Haden Kollins
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.